Acura Pharmaceuticals (ACUR) Stock Chart & Stock Price History $0.0003 0.00 (0.00%) As of 08/25/2025 Add Compare Share Share Chart Stock AnalysisChartSEC FilingsShort InterestBuy This Stock Acura Pharmaceuticals Stock Price Performance The Acura Pharmaceuticals (ACUR) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 92.11%, with a year-to-date return of 50.00%. In the past month, the stock has decreased 40.00%, reflecting recent market activity. As of the latest close, Acura Pharmaceuticals traded at $0.00 with a market cap of $20 thousand and volume of 0 shares. Five years ago, the stock traded at $0.29, representing a 99.90% decrease over that period. At the time, it had a market cap of $5.57 million and a volume of 6,370 shares. Receive ACUR Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Acura Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. 5 Day Performance0.00%1 Month Performance-40.00%3 Month PerformanceN/AYear-To-Date Performance+50.00%1 Year Performance-92.11%5 Year Performance-99.90% ACUR Stock Chart for Tuesday, August, 26, 2025 ACUR Chart by TradingView Acura Pharmaceuticals Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/22/2025$0.00$0.00$0.00$0.001,000 shs$20,000.0008/21/2025$0.00$0.00$0.00$0.001,000 shs$20,000.0008/20/2025$0.00$0.00$0.00$0.001,000 shs$20,000.0008/19/2025$0.00$0.00$0.00$0.001,000 shs$20,000.0008/18/2025$0.01$0.00-94.00%$0.00$0.00643 shs$20,000.0008/15/2025$0.01$0.01$0.01$0.001,843 shs$332,000.0008/14/2025$0.00$0.01+900.00%$0.01$0.001,843 shs$332,000.0008/13/2025$0.00$0.00$0.00$0.005,000 shs$33,000.0008/12/2025$0.00$0.00$0.00$0.005,000 shs$33,000.0008/11/2025$0.00$0.00$0.00$0.005,000 shs$33,000.00 Get the Latest News and Ratings for ACUR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Acura Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 08/07/2025$0.00$0.00$0.00$0.001,904 shs$33,000.0008/06/2025$0.00$0.00$0.00$0.001,904 shs$33,000.0008/01/2025$0.00$0.00$0.00$0.0028 shs$33,000.0007/30/2025$0.00$0.00$0.00$0.00757 shs$33,000.0007/29/2025$0.00$0.00$0.00$0.00757 shs$33,000.0007/25/2025$0.00$0.00$0.00$0.00800 shs$33,000.00 Related Companies LLY Stock Chart JNJ Stock Chart ABBV Stock Chart MRK Stock Chart PFE Stock Chart BMY Stock Chart ZTS Stock Chart RPRX Stock Chart JAZZ Stock Chart CORT Stock Chart Receive ACUR Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Acura Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (OTCMKTS:ACUR) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBREAKING: Meta, Apple and NASA rush to invest in new "E.I." techBig Tech and even NASA are racing to back a breakthrough known as “E.I. Tech,” set to launch September 1st. Ex...Behind the Markets | SponsoredTrump’s national nightmare is hereWhile the headlines focus on global conflicts, there’s a very different crisis brewing at home. Washington has...Porter & Company | SponsoredIt’s game over for Central BanksCentral banks are losing control. Inflation isn’t fixed, debt is exploding, and stocks have never looked more ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acura Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acura Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access